RECRUITING

Radiation Free Study

Description

This is a prospective, randomized, unblinded, multi-center study. Sites were selected from different geographies (EU and US) with different clinical practice to ensure the results are more generalizable. Primary objective is to demonstrate that the average procedure fluoroscopy time using LumiGuide is lower compared to conventional fluoroscopy guidance in Fenestrated Endovascular Aortic Repair (FEVAR)

Conditions

Aortic Aneurysm
Talk to us

Related Conditions:

Aortic Aneurysm

Study Overview

On this page

Study Details

Study overview

This is a prospective, randomized, unblinded, multi-center study. Sites were selected from different geographies (EU and US) with different clinical practice to ensure the results are more generalizable. Primary objective is to demonstrate that the average procedure fluoroscopy time using LumiGuide is lower compared to conventional fluoroscopy guidance in Fenestrated Endovascular Aortic Repair (FEVAR)

Radiation Free Study

Radiation Free Study

Condition
Aortic Aneurysm
Intervention / Treatment

-

Contacts and Locations

Birmingham

University of Alabama, Birmingham, Alabama, United States, 35249

Worcester

University of Massachusetts, Worcester, Massachusetts, United States, 01655

Philadelphia

University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104

Dallas

University of Texas Southwestern Medical Center, Dallas, Texas, United States, 75390

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Subject will be undergoing a primary Fenestrated Endovascular Aortic Repair (FEVAR) procedure (including subjects with prior infrarenal EVAR or open repair) that includes the incorporation of visceral arteries into the repair.
  • * Subject is able to give informed consent and is 18 years of age or older, or of legal age to give informed consent per state or national law.
  • * Subject has a life expectancy of at least 2 years
  • * Target vessels to be included are the Celiac Trunk, Superior Mesenteric Artery and Renal Arteries
  • * Subjects undergoing an endovascular procedure that include branches or iliac branched devices (IBD) in the repair
  • * Subject treated for re-intervention / staged procedure post-primary FEVAR procedure
  • * Subjects intended to be treated for more than 4 target vessels (not counting the contralateral gate)
  • * Subject treated for an emergent (\<24hrs after emergence) procedure
  • * Subject with connective tissue disorder eg, Marfan's or Ehlers Danlos Syndrome
  • * Subject with contrast allergies
  • * Subject participates in a potentially confounding drug or device trial during the course of the study. Co-enrollment in concurrent trials may be allowed provided that pre-approval is obtained from Philips.
  • * All vulnerable subjects such as immuno-compromised subjects, subjects lacking the capacity to provide consent, patients in emergency situations, pregnant or breast-feeding women, or any other subject who meets an exclusion criteria, according to applicable national laws, if any.
  • * Subject unwilling or unable to comply with the protocol unable to understand verbal and/or written informed consent

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Philips Clinical & Medical Affairs Global,

Study Record Dates

2026-06-30